Home World Politics Business Tech Health Science Climate Education

Balanced coverage of the week's biggest story. See every side. Know the truth.

By signing up for the Story of the Week newsletter you agree to our privacy policy.

Product

For You
Trending
Blindspot
Local
Compare
Brief
Trust

Topics

World
Politics
Business
Tech
Health
Science

Regions

Africa
Europe
Asia-Pacific
Americas
Middle East

Company

About
Contact
All topics
My Bias
Privacy
Terms & DMCA
Partner Offers

KODAWIRE

KODAWIRE

© 2026 Kodawire

About Contact Privacy Terms Top

/

/

Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript

1 sources

Seeking Alpha (US)1h ago

Center

Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript

Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S.

Spectrum

L 0%C 100%R 0%